| Bioactivity | RIPK1-IN-21 (Compound I-5) is an inhibitor of RIPK1 with an EC50 value of 14.8 nM. RIPK1-IN-21 can be used in the research of neurodegenerative, autoimmune, and inflammatory diseases[1]. |
| Target | EC50: 14.8 nM (RIPK1). |
| CAS | 3016304-64-3 |
| Formula | C17H14F2N4O |
| Molar Mass | 328.32 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sabnis R W. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, AutoimmSabnis R W. Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases[J]. ACS Medicinal Chemistry Letters, 2024.une, and Inflammatory Diseases[J]. ACS Medicinal Chemistry Letters, 2024. |
RIPK1-IN-21
CAS: 3016304-64-3 F: C17H14F2N4O W: 328.32
RIPK1-IN-21 (Compound I-5) is an inhibitor of RIPK1 with an EC50 value of 14.8 nM. RIPK1-IN-21 can be used in the resear
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.